Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $21.29

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus rating of “Buy” by the ten research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $21.29.

Several research firms recently weighed in on STOK. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Chardan Capital initiated coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Finally, Leerink Partners initiated coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the completion of the sale, the insider now directly owns 47,332 shares in the company, valued at approximately $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock worth $809,421 over the last three months. 11.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of STOK. Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the period. State Street Corp grew its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares during the period. RTW Investments LP increased its stake in Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after buying an additional 71,647 shares during the last quarter.

Stoke Therapeutics Stock Up 0.4 %

Stoke Therapeutics stock opened at $9.00 on Monday. The stock has a market cap of $476.70 million, a PE ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a 12-month low of $4.09 and a 12-month high of $17.58. The business’s 50-day moving average price is $11.91 and its two-hundred day moving average price is $13.04.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.